InflaRx N.V. (NASDAQ:IFRX) Receives Average Rating of “Moderate Buy” from Brokerages

InflaRx N.V. (NASDAQ:IFRX) has been given an average rating of “Moderate Buy” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $6.1667.

A number of research firms recently issued reports on IFRX. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research note on Monday, December 29th. Guggenheim cut their price target on shares of InflaRx from $22.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 20th. Raymond James Financial reiterated an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of InflaRx in a research report on Tuesday, December 30th. Finally, Leerink Partners restated a “market perform” rating and set a $2.00 price objective (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd.

InflaRx Trading Down 1.1%

NASDAQ:IFRX opened at $0.93 on Friday. InflaRx has a 1 year low of $0.71 and a 1 year high of $1.94. The stock has a 50-day moving average price of $0.92 and a two-hundred day moving average price of $1.13. The stock has a market cap of $67.23 million, a price-to-earnings ratio of -1.22 and a beta of 1.48.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.04) million for the quarter, compared to analyst estimates of $0.03 million. Sell-side analysts forecast that InflaRx will post -1.04 earnings per share for the current year.

Institutional Trading of InflaRx

Several hedge funds and other institutional investors have recently modified their holdings of IFRX. Cubist Systematic Strategies LLC grew its holdings in shares of InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares in the last quarter. HRT Financial LP bought a new stake in InflaRx in the 4th quarter valued at approximately $47,000. Concurrent Investment Advisors LLC lifted its stake in InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares in the last quarter. Insigneo Advisory Services LLC acquired a new position in InflaRx during the 4th quarter worth approximately $61,000. Finally, Quadrature Capital Ltd acquired a new position in InflaRx during the 4th quarter worth approximately $104,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.